Skip to content
Invitrocue - Transforming bioanalytics
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Patient-derived Organoid (PDO)
    • Immunomodulatory Assays
    • Customized Assays and Disease Modelling
    • Invivocue – Humanized Mice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Patient-derived Organoid (PDO)
    • Immunomodulatory Assays
    • Customized Assays and Disease Modelling
    • Invivocue – Humanized Mice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)

Preliminary Final Report

August 31, 2018

Appendix 4E for the year ended 30 June 2018
preliminary final report august 2018

Categories ASX Announcements, Financial Reports
Post navigation
Change in substantial holding
Business updates

Recent Posts

  • Xylonix and Invitrocue form strategic clinical alliance to validate new method for combating IL-6 pathologies
  • Invitrocue and Angsana partner with Averywell to advance early lung cancer detection across Asia
  • Invitrocue announces merger with Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories
  • Strategic partnership & Financial advisor appointment
  • Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean

GET IN TOUCH

51 Science Park Road, #01-11/13 The Aries, Singapore Science Park II Singapore 117586

GENERAL / PHARMACOLOGY ENQUIRIES:

+65 6460 0497
contact@invitrocue.com

ONCO-PDO ENQUIRIES:

+65 6819 0181
onco-pdo@invitrocue.com

SERVICES

Home
About Us
Oncology
Preclinical Services
Investors
News & Resources
Contact Us

Logo Invitrocue
Icon-twitter-x Facebook-f Linkedin-in Youtube

© Copyright 2026 Invitrocue. All rights reserved
Impressum | Privacy Policy | Cookies Policy | Cookie Settings